EVOTEC has acquired Cyprotex PLC
Target Company Name:
Country:
Advisory:
Sector:
Partner:
Country:
Advisory:
Sector:
Partner:
Evotec acquired 100 percent of the outstanding shares of Cyprotex in an all-cash transaction valued at £55.7 million effective December 15, 2016.
Sale of Preclinical ADME-Toxicology Services Provider Cyprotex PLC to Evotec
Advisor :
Brown Gibbons Lang & Company
Brown Gibbons Lang & Company
Experts who worked on this transaction
Loading...
